ALRN Aileron Therapeutics Inc.

0.76
-0.02  -3%
Previous Close 0.79
Open 0.79
Price To Book 0.93
Market Cap 21,252,676
Shares 27,810,358
Volume 264,536
Short Ratio
Av. Daily Volume 329,734
Stock charts supplied by TradingView

NewsSee all news

  1. Aileron Therapeutics Announces the Promotion of Richard J. Wanstall to Chief Financial Officer and Treasurer

    WATERTOWN, Mass., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, announced today the promotion of Richard J.

  2. Aileron Therapeutics Reports Third Quarter 2019 Results

    Announced positive interim results from its ongoing Phase 2a clinical trial evaluating the combination of ALRN-6924 and Pfizer's IBRANCE® (palbociclib) for the treatment of patients with tumors harboring wild-type p53

  3. Aileron Therapeutics to Report Third Quarter 2019 Financial Results on November 7th

    WATERTOWN, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, today announced that the Company will host a

  4. Aileron to Present Nonclinical Myelopreservation Data for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference on October 29th

    Nonclinical research showed that ALRN-6924 prevented the toxic side effects of chemotherapy in normal cells without inhibiting the anti-cancer activity of chemotherapy. ALRN-6924 could enable a precision-medicine

  5. Aileron Presents Positive Interim Phase 2a Data for ALRN-6924 in Combination with Pfizer's Palbociclib at the 2019 Congress of the European Society for Medical Oncology

    WATERTOWN, Mass., Sept. 28, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer patients, announced the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Noted that development to be discontinued - no pivotal trial.
ALRN-6924
Peripheral T-cell lymphoma (PTCL)
Phase 1/1b trial ongoing.
ALRN-6924 and Cytarabine (Ara-C)
Acute myeloid leukemia (AML); Myelodysplastic syndrome (MDS)
Phase 2a final data due 2Q 2020.
ALRN-6924 and IBRANCE (palbociclib)
Solid tumors
Phase 1 has been initiated.
ALRN-6924 and Paclitaxel
Breast cancer
Phase 1b/2 dose-optimization data due 2Q 2020.
ALRN-6924
Small Cell Lung Cancer (SCLC)

Latest News

  1. Aileron Therapeutics Announces the Promotion of Richard J. Wanstall to Chief Financial Officer and Treasurer

    WATERTOWN, Mass., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, announced today the promotion of Richard J.

  2. Aileron Therapeutics Reports Third Quarter 2019 Results

    Announced positive interim results from its ongoing Phase 2a clinical trial evaluating the combination of ALRN-6924 and Pfizer's IBRANCE® (palbociclib) for the treatment of patients with tumors harboring wild-type p53

  3. Aileron Therapeutics to Report Third Quarter 2019 Financial Results on November 7th

    WATERTOWN, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, today announced that the Company will host a

  4. Aileron to Present Nonclinical Myelopreservation Data for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference on October 29th

    Nonclinical research showed that ALRN-6924 prevented the toxic side effects of chemotherapy in normal cells without inhibiting the anti-cancer activity of chemotherapy. ALRN-6924 could enable a precision-medicine

  5. Aileron Presents Positive Interim Phase 2a Data for ALRN-6924 in Combination with Pfizer's Palbociclib at the 2019 Congress of the European Society for Medical Oncology

    WATERTOWN, Mass., Sept. 28, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer patients, announced the

  6. Aileron to Present Interim Phase 2a Clinical Data for ALRN-6924 in Combination with Pfizer's IBRANCE® (palbociclib) in Patients with MDM2-Amplified Cancers at the 2019 Congress of the European Society for Medical Oncology

    WATERTOWN, Mass., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer patients, today announced that an

  7. Aileron Therapeutics Announces Management Change

    WATERTOWN, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced

  8. Aileron Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference in New York

    WATERTOWN, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced